Latest Lead News

Biome Australia has partnered with the Food and Beverage Accelerator (FaBA) to jointly develop its promising BMB18 probiotic strain, leveraging $50 million in Australian government funding while retaining full IP ownership.

Evion Group has successfully raised $1.33 million through a rights issue, positioning itself to accelerate production at its Panthera JV in India. The company also announced a bonus options offer to reward shareholders and support future expansion.

Delorean Corporation has marked a pivotal quarter with the Financial Investment Decision for its SA1 Bioenergy Project and steady progress on the Yarra Valley Water facility, underpinning its transition to infrastructure ownership in Australia's bioenergy sector.

Magnum Mining and Exploration Limited has announced a pro-rata non-renounceable entitlement offer to raise up to $1.94 million, aiming to fund exploration at its Palmares and Buena Vista projects. The offer includes new shares and free options, presenting both opportunity and dilution risks for shareholders.

Magnum Mining and Exploration Limited has launched a $1.9 million non-renounceable entitlement offer to fund its key projects, alongside significant board changes aimed at conserving cash.

Piedmont Lithium reported record Q4 2024 shipments of spodumene concentrate, modestly exceeding guidance, while preparing to merge with Sayona Mining to consolidate North American lithium operations.

Xref Limited reported a solid 10% revenue increase to $10.9 million in H1 FY2025, even as a proposed acquisition by SEEK was narrowly rejected by shareholders. The company plans to continue its growth trajectory as an independent ASX-listed entity with new product launches on the horizon.

Sigma Healthcare has secured Federal Court approval for its acquisition of Chemist Warehouse, marking a pivotal step in reshaping Australia's pharmaceutical retail landscape.

Pro Medicus has inked a $53 million, seven-year contract with BayCare to deploy its Visage 7 cloud-based imaging platform across Florida’s largest healthcare system, marking a major step in its North American expansion.

Argenica Therapeutics reports compelling preclinical evidence that its lead candidate ARG-007 significantly reduces brain cell damage and inflammation in moderate traumatic brain injury models, marking a promising step toward new TBI treatments.

Viridis Mining and Minerals Limited has been reinstated to ASX quotation following a capital raising announcement, ending its trading suspension and signaling renewed investor confidence.

Viridis Mining and Minerals has raised A$3.5 million through a placement to fund critical development milestones for its Colossus Rare Earth Element project, following a major resource upgrade.